"If your that sure why don't you go all in at this low entry point as that would make it investment grade by your standards."
It's not that I am necessarily that sure about it, but what else could it be? For how much longer could Celgene possibly continue running the ruler over MSB? Two years is quite a protracted due diligence period, by any measure.
Besides, wherever did you come to the view that any partnership deal would suddenly make MSB investment grade in my eyes?
Companies whose ongoing existence owes itself to the kindness of strangers do not fit my definition of investment grade.
Ann: Positive Nine Month RA Results For Mesoblast Cell Therapy, page-32
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
-0.045(2.98%) |
Mkt cap ! $1.672B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $8.307M | 5.669M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 24 | 151320 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 55652 | 2 |
View Market Depth
| Last trade - 16.10pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |